

# CENTER FOR DRUG EVALUATION AND RESEARCH

**APPLICATION:NDA 20036/S-015**

## CONTENTS

	Included	Pending Completion	Not Prepared	Not Required
Approval Letter	X			
Tentative Approval Letter				X
Approvable Letter			X	
Final Printed Labeling		X		
Medical Review(s)	X			
Chemistry Review(s)	X			
EA/FONSI			X	
Pharmacology Review(s)	X			
Statistical Review(s)	X			
Microbiology Review(s)			X	
Clinical Pharmacology Biopharmaceutics Review(s)	X			
Bioequivalence Review(s)			X	
Administrative Document(s)	X			
Correspondence	X			

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**Approval Package for:**

**Application Number:NDA 20036/S-015**

**Trade Name: Aredia**

**Generic Name:(pamidronate disodium for injection)**

**Sponsor:Novartis Pharmaceuticals Corporation**

**Approval Date:September 22, 1998**

**Indication: Provides for identical changes in the INDICATIONS AND USAGE, CLINICAL PHARMACOLOGY, ADVERSE REACTIONS, and DOSAGE AND ADMINISTRATION sections of the currently approved labeling.**

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**Application Number: NDA 20036/S-015**

**APPROVAL LETTER**

DEPARTMENT OF HEALTH & HUMAN SERVICES

D. Catterson

Food and Drug Administration  
Rockville MD 20857

NDA 20-927  
NDA 20-036/S-015, S-016

SEP 22 1998

Novartis Pharmaceuticals Corporation  
59 Route 10  
East Hanover, NJ 07936

Attention: Ellen Cutler  
Assistant Director, Drug Regulatory Affairs

Dear Ms. Cutler:

Please refer to your new drug application (NDA) dated September 22, 1997, received September 22, 1997, and submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Aredia® (pamidronate disodium for injection).

We acknowledge receipt of your submissions dated December 3, 1997; February 4, August 21, and September 17, 1998. The user fee goal date for this application is September 22, 1998.

Please also refer to the approved NDA 20-036/S-011 which provided for the use of Aredia® (pamidronate disodium for injection) in conjunction with standard antineoplastic therapy for the treatment of osteolytic bone metastases of breast cancer. This new drug application provides the results of the one-year extension period of the two Phase 3 studies that were submitted to support the approval of the NDA 20-036/S-011.

Further, please refer to your September 22, 1997 supplemental new drug application NDA 20-036/S-016. This supplement and NDA 20-927 provide for identical changes to the INDICATIONS AND USAGE, CLINICAL PHARMACOLOGY, ADVERSE REACTIONS, and DOSAGE AND ADMINISTRATION sections of the currently approved labeling. We also note that NDA 20-036/S-015, submitted June 4, 1998, is superseded by Supplement-016 and will be retained in your NDA file. All changes submitted under S-015 should be incorporated into the final printed labeling (FPL) for S-016.

We have completed the review of this application, as amended, and the supplemental new drug application and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed labeling text. Accordingly, the application (NDA 20-927) and the supplement application (NDA 20-036/S-016) are approved effective on the date of this letter.

We remind you that you must comply with the requirements set forth under 21 CFR 314.80 and 314.81 for the approved NDA. All supplements and other submissions

should be addressed to the original NDA 20-036 for this drug product, not to this NDA 20-927, except for the 20 copies of final printed labeling and advertising material as noted below.

The FPL must be identical to the enclosed labeling (text for the package insert) except for the addition of changes submitted under NDA 20-036/S-015. Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved NDA 20-927." Approval of this submission by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division, one copy to the Division of Endocrine and Metabolic Drug Products, and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Debra Catterson, Project Manager, at (301) 827-1544.

Sincerely,

*RS* *M.D.*  
Robert L. Justice, M.D.  
Acting Director  
Division of Oncology Drug Products  
Office of Drug Evaluation I  
Center for Drug Evaluation and Research

Enclosure

cc:

Original NDA 20-927  
HFD-150/Div. Files  
Archival NDA 20-036/HFD-510 (with labeling - 4 copies)  
HFD-510/NDA 20-036  
HF-2/MedWatch (with labeling)  
HFD-002/ORM (with labeling)  
HFD-101/ADRA (with labeling)  
HFD-40/DDMAC (with labeling)  
HFD-613/OGD (with labeling)  
HFD-95/DDMS (with labeling)  
HFD-810/DNDC Division Director  
DISTRICT OFFICE  
HFD-150/DCatterson  
HFD-150/GWilliams  
HFD-150/RJustice  
HFD-150/LHsieh  
HFD-150/RWood  
HFD-150/HZheng  
HFD-150/PAndrews  
HFD-150/SWang  
HFD-150/GChen  
HFD-150/JDuan  
HFD-150/ARahman

Concurrence on enclosed labeling: HFD-510/BSchneider 9.18.98/ EGalliers 9.18.98

Drafted by: DCatterson/9.18.98/c:\mydocuments\aredia\action letter.doc

Initialed by:

/DPease/9.22.98  
/GWilliams/9.21.98  
/HZheng/9.21.98  
/PAndrews/9.21.98  
/GChen/9.22.98  
/JSimmons/9.22.98  
/RJustice/9.21.98

final: DCatterson/9.22.98 *DPease 9-22-98*

**APPROVAL (AP) - NDA 20-927**  
**APPROVAL (AP) - NDA 20-036/S-016**  
**ACK/RET - NDA 20-036/S-015**